Fulcrum Therapeutics (FULC) FCF Margin (2020 - 2024)
Fulcrum Therapeutics (FULC) reported FCF Margin of 73.64% for Q2 2024, up 246818.0% year-over-year from N/an in Q3 2023, and up 102.76% quarter-over-quarter from 2667.62% in Q4 2023.
Fulcrum Therapeutics (FULC) FCF Margin (2020 - 2024) Analysis & Trends
Fulcrum Therapeutics (FULC) has 5 years of FCF Margin data on file, last reported at 73.64% in Q2 2024.
- FCF Margin for Q2 2024 came in at 73.64%, up 246818.0% year-over-year; the trailing twelve-month figure through Jun 2025 was 81.46% (down 6601.0% YoY), and the FY2024 annual result was 3.12%, up 325795.0% from the prior year.
- FCF Margin improved to 73.64% in Q2 2024 per FULC's latest filing, from 2667.62% in the prior quarter.
- Over five years, FCF Margin peaked at 73.64% in Q2 2024 and troughed at 8201.69% in Q1 2023.
- A 5-year average of 1689.49% and a median of 862.35% in 2022 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2024: FCF Margin slumped 733935 bps in 2023, then surged 246818 bps in 2024.
- A 5-year view of FCF Margin shows it stood at 454.86% in 2020, then increased by 10 bps to 409.27% in 2021, then tumbled by 538 bps to 2609.49% in 2022, then dropped by 2 bps to 2667.62% in 2023, then soared by 103 bps to 73.64% in 2024.
- Business Quant data shows FULC's FCF Margin at 73.64% in Q2 2024, 2667.62% in Q4 2023, and 3026.48% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -3.98% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 73.64% |
| Dec 31, 2023 | -2,667.62% |
| Sep 30, 2023 | -3,026.48% |
| Jun 30, 2023 | -2,394.55% |
| Mar 31, 2023 | -8,201.69% |
| Dec 31, 2022 | -2,609.49% |
| Sep 30, 2022 | -2,380.81% |
| Jun 30, 2022 | -1,524.12% |
| Mar 31, 2022 | -862.35% |
| Dec 31, 2021 | -409.27% |
| Sep 30, 2021 | -464.84% |
| Jun 30, 2021 | -424.74% |
| Mar 31, 2021 | -339.65% |
| Dec 31, 2020 | -454.86% |
| Sep 30, 2020 | -248.76% |
| Jun 30, 2020 | -736.75% |
| Mar 31, 2020 | -2,048.93% |